Table 2.
Association between early thromboprophylaxis and mortality by pre-existing medical conditions
| Pre-existing medical conditions | Odds ratios (95% CI) | P-value |
|---|---|---|
| Chronic respiratory disease (n = 106,833) | ||
| VTE prophylaxis | ||
| Yes | Ref | |
| No | 1.38 (1.27–1.50) | < 0.001 |
| Contraindicated | 1.10 (0.99–1.23) | 0.069 |
| Not indicated | 1.31 (1.15–1.51) | < 0.001 |
| Chronic cardiovascular disease (n = 131,038) | ||
| VTE prophylaxis | ||
| Yes | Ref | |
| No | 1.46 (1.34–1.57) | < 0.001 |
| Contraindicated | 1.28 (1.18–1.40) | < 0.001 |
| Not indicated | 1.24 (1.09–1.41) | 0.001 |
| Chronic renal failure (n = 48,970) | ||
| VTE prophylaxis | ||
| Yes | Ref | |
| No | 1.34 (1.20–1.49) | < 0.001 |
| Contraindicated | 1.32 (1.17–1.49) | < 0.001 |
| Not indicated | 1.32 (1.10–1.57) | 0.026 |
| Chronic liver disease (n = 25,058) | ||
| VTE prophylaxis | ||
| Yes | Ref | |
| No | 1.27 (1.11–1.45) | < 0.001 |
| Contraindicated | 1.23 (1.11–1.37) | < 0.001 |
| Not indicated | 1.30 (1.03–1.63) | 0.026 |
| Metastatic cancer (n = 56,101) | ||
| VTE prophylaxis | ||
| Yes | Ref | |
| No | 1.37 (1.21–1.54) | < 0.001 |
| Contraindicated | 1.34 (1.17–1.54) | < 0.001 |
| Not indicated | 1.29 (1.03–1.63) | 0.029 |
Adjusted for Australian and New Zealand Risk of Death (ANZROD). ANZROD is derived from patient and clinical characteristics, including the Acute Physiology and Chronic Health Evaluation (APACHE) III, ICU admission source, admission diagnoses, Acute Physiology score (APS), APACHE III chronic health score, treatment limitation, and ventilation status. VTE-Venous thromboembolism